Molecular Partners AG (MOLN) expanded its strategic collaboration with Orano Med to include the development of an additional six targeted alpha radio-therapies for cancer, the companies said Sunday.
The companies entered into an initial agreement in January 2024 to co-develop four programs.
Under the expanded collaboration, Molecular Partners will lead the development of the six additional programs, with an option for Orano Med to move for the co-development of two of the six programs.
Financial terms were not disclosed.
The company said it expects the deal to have no immediate impact on its fiscal 2025 financial outlook.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。